| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.8 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.8 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | -0.011 | 0.9 |